745783-81-7 Usage
Description
(S)-(+)-1-INDANYL ISOCYANATE is a chemical compound that belongs to the class of isocyanates, characterized by its specific stereochemical configuration denoted by the (S)-(+)prefix. It is known for its reactivity and is commonly utilized in the production of polyurethane foams, coatings, and adhesives. (S)-(+)-1-INDANYL ISOCYANATE features a highly reactive isocyanate group, which makes it valuable in the synthesis of various polymers and organic compounds. Careful handling and adherence to safety precautions are essential when working with this compound due to its reactivity.
Uses
Used in the Chemical Industry:
(S)-(+)-1-INDANYL ISOCYANATE is used as a key component in the production of polyurethane foams for its ability to react with other chemicals to form versatile materials with unique properties. These foams are utilized in a wide range of applications, including insulation, cushioning, and furniture manufacturing.
Used in the Coatings Industry:
In the coatings industry, (S)-(+)-1-INDANYL ISOCYANATE is used as a reactive monomer to create coatings with enhanced durability, flexibility, and resistance to various environmental factors. These coatings are applied in automotive, construction, and industrial settings to protect surfaces and extend their lifespan.
Used in the Adhesives Industry:
(S)-(+)-1-INDANYL ISOCYANATE is employed as a critical ingredient in the formulation of high-performance adhesives. Its reactivity allows for the creation of strong bonds between different materials, making it suitable for use in various applications such as construction, automotive, and packaging industries.
Used in the Synthesis of Polymers and Organic Compounds:
(S)-(+)-1-INDANYL ISOCYANATE is used as a building block in the synthesis of various polymers and organic compounds due to its highly reactive isocyanate group. This enables the development of new materials with specific properties tailored to meet the demands of different industries, including pharmaceuticals, agriculture, and electronics.
Check Digit Verification of cas no
The CAS Registry Mumber 745783-81-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,4,5,7,8 and 3 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 745783-81:
(8*7)+(7*4)+(6*5)+(5*7)+(4*8)+(3*3)+(2*8)+(1*1)=207
207 % 10 = 7
So 745783-81-7 is a valid CAS Registry Number.
745783-81-7Relevant articles and documents
Benzylic C-H isocyanation/amine coupling sequence enabling high-throughput synthesis of pharmaceutically relevant ureas
Krska, Shane W.,Lin, Shishi,Nkulu, Leah E.,Stahl, Shannon S.,Suh, Sung-Eun
, p. 10380 - 10387 (2021/08/12)
C(sp3)-H functionalization methods provide an ideal synthetic platform for medicinal chemistry; however, such methods are often constrained by practical limitations. The present study outlines a C(sp3)-H isocyanation protocol that enables the synthesis of diverse, pharmaceutically relevant benzylic ureas in high-throughput format. The operationally simple C-H isocyanation method shows high site selectivity and good functional group tolerance, and uses commercially available catalyst components and reagents [CuOAc, 2,2′-bis(oxazoline) ligand, (trimethylsilyl)isocyanate, andN-fluorobenzenesulfonimide]. The isocyanate products may be used without isolation or purification in a subsequent coupling step with primary and secondary amines to afford hundreds of diverse ureas. These results provide a template for implementation of C-H functionalization/cross-coupling in drug discovery.
Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach
Ni, Shuaishuai,Yuan, Yaxia,Huang, Jin,Mao, Xiaona,Lv, Maosheng,Zhu, Jin,Shen, Xu,Pei, Jianfeng,Lai, Luhua,Jiang, Hualiang,Li, Jian
supporting information; experimental part, p. 5295 - 5298 (2010/02/28)
This work describes an integrated approach of de novo drug design, chemical synthesis, and bioassay for quick identification of a series of novel small molecule cyclophilin A (CypA) inhibitors (1-3). The activities of the two most potent CypA inhibitors (3h and 3i) are 2.59 and 1.52 nM, respectively, which are about 16 and 27 times more potent than that of cyclosporin A. This study clearly demonstrates the power of our de novo drug design strategy and the related program LigBuilder 2.0 in drug discovery.
